DrugPatentWatch Database Preview
Details for Patent: 8,530,694
» See Plans and Pricing
Which drugs does patent 8,530,694 protect, and when does it expire?
Patent 8,530,694 protects NINLARO and is included in one NDA.
This patent has fifty-nine patent family members in thirty-five countries.
Summary for Patent: 8,530,694
| Title: | Proteasome inhibitors |
| Abstract: | The present invention provides novel compounds useful as proteasome inhibitors. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various diseases. |
| Inventor(s): | Olhava; Edward J. (Newton, MA), Danca; Mihaela Diana (Mendham, NJ) |
| Assignee: | Millennium Pharmaceuticals, Inc. (Cambridge, MA) |
| Application Number: | 13/209,511 |
|
Patent Claim Types: see list of patent claims | Compound; Composition; Use; |
Drugs Protected by US Patent 8,530,694
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Millennium Pharms | NINLARO | ixazomib citrate | CAPSULE;ORAL | 208462-001 | Nov 20, 2015 | RX | Yes | No | Start Trial | Start Trial | Y | Y | USE IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY | Start Trial | ||
| Millennium Pharms | NINLARO | ixazomib citrate | CAPSULE;ORAL | 208462-002 | Nov 20, 2015 | RX | Yes | No | Start Trial | Start Trial | Y | Y | USE IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY | Start Trial | ||
| Millennium Pharms | NINLARO | ixazomib citrate | CAPSULE;ORAL | 208462-003 | Nov 20, 2015 | RX | Yes | Yes | Start Trial | Start Trial | Y | Y | USE IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY | Start Trial | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 8,530,694
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Argentina | 067824 | Start Trial | |||
| Australia | 2007357338 | Start Trial | |||
| Brazil | PI0721905 | Start Trial | |||
| Canada | 2695082 | Start Trial | |||
| Chile | 2008002159 | Start Trial | |||
| China | 101772507 | Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
